CL2009001284A1 - Anticuerpos o fragmentos de union a antigeno del mismo que se unen a il-21r; composicion farmaceutica que lo comprende; acidos nucleicos codificantes; vectores de expresion y celulas huesped aisladas; kit de diagnostico que comprende a dichos anticuerpos - Google Patents

Anticuerpos o fragmentos de union a antigeno del mismo que se unen a il-21r; composicion farmaceutica que lo comprende; acidos nucleicos codificantes; vectores de expresion y celulas huesped aisladas; kit de diagnostico que comprende a dichos anticuerpos

Info

Publication number
CL2009001284A1
CL2009001284A1 CL2009001284A CL2009001284A CL2009001284A1 CL 2009001284 A1 CL2009001284 A1 CL 2009001284A1 CL 2009001284 A CL2009001284 A CL 2009001284A CL 2009001284 A CL2009001284 A CL 2009001284A CL 2009001284 A1 CL2009001284 A1 CL 2009001284A1
Authority
CL
Chile
Prior art keywords
antibodies
antigen
pharmaceutical composition
diagnostic kit
bind
Prior art date
Application number
CL2009001284A
Other languages
English (en)
Spanish (es)
Inventor
Yulia Vugmeyster
Laird Bloom
Davinder Gill
Deborah A Young
David Lowe
Viia Valge-Archer
Original Assignee
Wyeth Corp
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41112652&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2009001284(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp, Medimmune Ltd filed Critical Wyeth Corp
Publication of CL2009001284A1 publication Critical patent/CL2009001284A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CL2009001284A 2008-05-23 2009-05-25 Anticuerpos o fragmentos de union a antigeno del mismo que se unen a il-21r; composicion farmaceutica que lo comprende; acidos nucleicos codificantes; vectores de expresion y celulas huesped aisladas; kit de diagnostico que comprende a dichos anticuerpos CL2009001284A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5550008P 2008-05-23 2008-05-23

Publications (1)

Publication Number Publication Date
CL2009001284A1 true CL2009001284A1 (es) 2009-11-27

Family

ID=41112652

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2009001284A CL2009001284A1 (es) 2008-05-23 2009-05-25 Anticuerpos o fragmentos de union a antigeno del mismo que se unen a il-21r; composicion farmaceutica que lo comprende; acidos nucleicos codificantes; vectores de expresion y celulas huesped aisladas; kit de diagnostico que comprende a dichos anticuerpos

Country Status (20)

Country Link
US (2) US8163884B2 (enExample)
EP (1) EP2297199A1 (enExample)
JP (1) JP2011523849A (enExample)
KR (1) KR20110040773A (enExample)
CN (1) CN102105491A (enExample)
AR (1) AR071885A1 (enExample)
AU (1) AU2009248809A1 (enExample)
CA (1) CA2724915A1 (enExample)
CL (1) CL2009001284A1 (enExample)
CO (1) CO6382184A2 (enExample)
IL (1) IL209328A0 (enExample)
MX (1) MX2010012811A (enExample)
MY (1) MY149448A (enExample)
NZ (1) NZ589330A (enExample)
PE (1) PE20100141A1 (enExample)
RU (1) RU2010152690A (enExample)
SA (1) SA109300315B1 (enExample)
TW (1) TW201000129A (enExample)
WO (1) WO2009143523A1 (enExample)
ZA (1) ZA201008335B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057128A (en) 1998-03-17 2000-05-02 Genetics Institute, Inc. MU-1, member of the cytokine receptor family
EP2518084B1 (en) * 2009-12-25 2016-11-30 Sekisui Medical Co., Ltd. Method for measuring human insulin and measurement reagent
EP2545080B1 (en) * 2010-03-12 2017-05-10 Alexion Pharmaceuticals, Inc. Npp1 fusion proteins
US9309318B2 (en) * 2012-10-17 2016-04-12 Amgen, Inc. Compositions relating to anti-IL-21 receptor antibodies
US20190185559A1 (en) * 2016-09-02 2019-06-20 The Brigham And Women's Hospital, Inc. Compositions and methods for treating neoplasias
US12134790B2 (en) 2017-09-27 2024-11-05 Inozyme Pharma, Inc. Methods of improving cardiovascular function and treating cardiovascular disease using a recombinant ectonucleotide pyrophosphatase phosphodiesterase (NPP1)
EP4162036A1 (en) 2020-06-09 2023-04-12 Inozyme Pharma, Inc. Soluble enpp1 or enpp3 proteins and uses thereof
US12012441B2 (en) 2020-10-26 2024-06-18 Neptune Biosciences Llc Engineered human IL-21 cytokines and methods for using the same
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7198789B2 (en) * 1998-03-17 2007-04-03 Genetics Institute, Llc Methods and compositions for modulating interleukin-21 receptor activity
US7189400B2 (en) * 1998-03-17 2007-03-13 Genetics Institute, Llc Methods of treatment with antagonists of MU-1
US6057128A (en) * 1998-03-17 2000-05-02 Genetics Institute, Inc. MU-1, member of the cytokine receptor family
US6576744B1 (en) * 1998-09-23 2003-06-10 Zymogenetics, Inc. Cytokine receptor zalpha11
UA84387C2 (ru) 1999-03-09 2008-10-27 Займодженетикс, Инк. Человеческий цитокин как лиганд зальфа рецептора и его применение
US6307024B1 (en) * 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
WO2000069880A1 (en) 1999-05-18 2000-11-23 Millennium Pharmaceuticals, Inc. Il-9/il-2 receptor-like molecules and uses thereof
ES2279809T3 (es) * 2000-04-05 2007-09-01 Zymogenetics, Inc. Receptores de citoquina zalfa11 solubles.
ATE346864T1 (de) 2000-05-11 2006-12-15 Genetics Inst Llc Mu-1, ein mitglied der cytokine rezeptor familie
EP2130919A1 (en) * 2001-11-05 2009-12-09 ZymoGenetics, Inc. IL-21 antagonists
US20040016010A1 (en) * 2002-04-17 2004-01-22 Marion Kasaian IL-21 receptor knockout animal and methods of use thereof
MXPA04012116A (es) * 2002-06-07 2005-04-19 Zymogenetics Inc Uso del il-21 en cancer y otras aplicaciones terapeuticas.
MXPA05000655A (es) * 2002-07-15 2006-02-22 Harvard College Metodos y composiciones para modular el desarrollo y la funcion de las celulas t helper (th).
MXPA05009556A (es) * 2003-03-14 2005-11-16 Wyeth Corp Anticuerpos contra receptor de il-21 humano y sus usos.
RU2005132458A (ru) * 2003-03-21 2006-03-20 Уайт (Us) Лечение иммунологических расстройств с использованием агонистов интерлейкина-21/рецептора интерлейкина-21
US7276478B2 (en) * 2003-09-25 2007-10-02 Zymogenetics, Inc. Methods of treating autoimmune diseases using IL-21
EP1753458A4 (en) * 2004-05-19 2009-07-22 Wyeth Corp MODULATION OF IMMUNOGLOBULIN PRODUCTION AND ATOPIC DISORDERS
MX2007001509A (es) 2004-08-05 2007-03-27 Wyeth Corp Antagonismo de la actividad del receptor de interleuquina 21.
CN101052419A (zh) * 2004-08-05 2007-10-10 惠氏公司 拮抗白介素－21受体活性
GT200600148A (es) * 2005-04-14 2006-11-22 Metodos para el tratamiento y la prevencion de fibrosis
WO2008081198A1 (en) 2007-01-05 2008-07-10 Imperial Innovations Ltd Blood assays for predicting inflammatory responses

Also Published As

Publication number Publication date
AR071885A1 (es) 2010-07-21
IL209328A0 (en) 2011-01-31
CN102105491A (zh) 2011-06-22
AU2009248809A1 (en) 2009-11-26
WO2009143523A1 (en) 2009-11-26
US20120264919A1 (en) 2012-10-18
JP2011523849A (ja) 2011-08-25
EP2297199A1 (en) 2011-03-23
MY149448A (en) 2013-08-30
SA109300315B1 (ar) 2012-08-28
ZA201008335B (en) 2014-04-30
PE20100141A1 (es) 2010-02-22
RU2010152690A (ru) 2012-06-27
MX2010012811A (es) 2011-05-19
KR20110040773A (ko) 2011-04-20
TW201000129A (en) 2010-01-01
NZ589330A (en) 2012-12-21
US20090298167A1 (en) 2009-12-03
CO6382184A2 (es) 2012-02-15
CA2724915A1 (en) 2009-11-26
US8163884B2 (en) 2012-04-24

Similar Documents

Publication Publication Date Title
CO2019001367A2 (es) Proteínas de unión de tipo anticuerpo biespecíficas que se unen específicamente a cd3 y cd123
CL2008002153A1 (es) Anticuerpo aislado o fragmanto de unión de antigeno del mismo que se une al receptor de il-18 (il-18r); molecula de ácido nucleico codificante; celula huesped que la comprende; composición farmaceutica; uso médico para tratar o prevenir una condición asociada con il-18r; método in vitro para inhibir la unión de il-18 al il-18r.
MX2021014952A (es) Molecula de union especifica para cd73 y uso de la molecula de union.
MX2020004578A (es) Composiciones de casz y metodos de uso.
CY1118576T1 (el) Πρωτεϊνες δεσμευομενες με αντιγονο ανθρωπινης il-23
EA201400568A1 (ru) Альбуминсвязывающие антитела и их связывающие фрагменты
MX2015000397A (es) Complejo del factor viii con xten y proteina del factor von willebrand, y sus usos.
CR11282A (es) Proteinas enlazadas al antigeno de celula de cepa mcdonough de felino humanas
UY36536A (es) Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123
PE20191463A1 (es) Anticuerpos biespecificos de union especifica pd1 y lag3
AR074399A1 (es) Moleculas biespecificas de union a egfr/igfir
CY1118880T1 (el) Ανθρωπινα anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
PE20181923A1 (es) Neoantigenos y metodos de su uso
EA201590545A1 (ru) Полипептиды, содержащие fc с измененным гликозилированием и сниженной эффекторной функцией
AR080914A1 (es) Proteinas de union al beta-amiloide
AR080229A1 (es) Proteinas de dominio de armazon de fibronectina que se unen a il -23 (interleucina 23)
CO6280541A2 (es) Anticuerpos monoclonales o fragmentos del mismo que se unen al recptor humano ox40
EA201791134A1 (ru) Полипептиды химерного фактора viii и их применение
CL2013001279A1 (es) Anticuerpo humano aislado o fragmento de union a antigeno del mismo que se une especificamente y neutraliza la actividad del ligando 1a de tipo tnf humano (htl1a); molecula de acido nucleico que lo codifica; vector de expresion; metodo de produccion; composicion farmaceutica que lo comprende; y su uso.
CR10652A (es) Anticuerpos monoclonales humanos especificos para light humano antagonistas
CL2012002081A1 (es) Anticuerpo humanizado que se une a la cadena alfa del receptor de il-7 humano (cd127); proteina de enlace a antigeno que comprende una o mas regiones determinantes de complementariedad de dicho anticuerpo; molecula de acido nucleico que codifica una anticuerpo o proteina de enalce; vector de expresion, celula huesped recombinante; procedimiento para la produccion de una proteina de enlace a antigeno; procedimiento para tratar enfermedad autoinmune o inflamatoria.
CL2012002095A1 (es) Polipéptido de unión biparatópico que comprende un primer dominio variable individual de inmunoglobulina (ig) que se une específicamente a un primer epítopo del péptido ß-amiloide (ßa) y un segundo dominio variable de ig que se une específicamente a un segundo epítopo del ßa, donde dichos epítopos del ßa no son idénticos; ácido nucleico que lo codifica; vector; célula hospedera; composición farmacéutica; método de preparación; y su uso en el tratamiento y/o prevención de depósitos del ßa
AR047729A1 (es) Anticuerpos terapeuticos que se unen a la apolipoproteina e (apoe)
PE20091713A1 (es) Inhibicion del receptor para la proteina estimulante del macrofago (ron), composiciones y metodos
ZA202201464B (en) Anti-tigit antibodies and application thereof